Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opening Session Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sep

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Opening Session Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

AACR Releases Annual Cancer Progress Report

Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance

KEYNOTE-826 Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer

TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer

Mobile CT Lung Cancer Screening May Expand Access for Underserved Populations